How Big Is the Hereditary Cancer Screening Market | Insights & Forecasts 2025

Code: MTA6154 Publication Date: Jul 2025

How big is the Hereditary Cancer Screening Market?

According to 6Wresearch internal database and industry insights, the Hereditary Cancer Screening Market was valued at USD 4.3 Billion in 2024 and is projected to reach USD 10.1 Billion by 2031, growing at a CAGR of 12.9% during the forecast period of 2025–2031.

The market is growing due to increasing awareness of genetic disorders, demand for early cancer detection, and advancements in next-gen sequencing technologies.

Key Growth Drivers of the Hereditary Cancer Screening Market

  • Rising incidence of breast, ovarian, and colorectal cancers
  • Advancements in next-generation sequencing and genetic diagnostics
  • Growing awareness of genetic risk factors and preventive screening
  • Favorable government initiatives and reimbursement policies
  • Increasing adoption of personalized medicine and early detection

Hereditary Cancer Screening Market Trends

Thehereditary cancer screening marketis witnessing rising demand for multi-gene panel testing over single-gene tests. Direct-to-consumer genetic testing services are gaining popularity, especially in developed regions. Integration of AI and bioinformatics is enhancing the accuracy of predictive diagnostics. Partnerships between diagnostic labs and pharma companies are increasing to deliver companion diagnostics. Awareness campaigns and genetic counseling services are expanding access across emerging markets.

Emerging Developments in the Hereditary Cancer Screening Market

Hereditarycancer screening market witnessed a breakthrough in innovation as liquid biopsy techniques are used to detect genetic mutations on a non-invasive basis, using samples of blood. Genetic information on complex data is also being analyzed through AI-based analytical software which enhances diagnostic accuracy, risk stratification of the patients. Firms are also increasing their list of hereditary cancer test panels with uncommon syndromes such as Lynch and Li-Fraumeni. Testing is becoming more available, particularly in less served regions, due to the possibility of collecting the samples remotely and tele-genetic counseling.

Major Companies in the Hereditary Cancer Screening Market

  • Myriad Genetics
  • Invitae Corporation
  • Fulgent Genetics
  • Ambry Genetics
  • Natera Inc.
  • Quest Diagnostics
  • Illumina Inc.
  • Color Genomics
  • GeneDx
  • Centogene N.V.

How Big Is the Hereditary Cancer Screening Market: FAQs

It was valued at USD 4.3 billion in 2024 and is expected to reach USD 10.1 billion by 2031.
The market is projected to grow at a CAGR of 12.9% from 2025 to 2031.
Next-generation sequencing (NGS), PCR, and microarray technologies.
Breast, ovarian, colorectal, prostate, and pancreatic cancers.
High test costs, limited awareness in developing regions, and data privacy concerns.
6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.
Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com
6Wresearch Support

Any Query

Call: +91-11-4302-4305
Email us: sales@6wresearch.com
Any Query? Click Here

Industry Events and Analyst Meet

Our Clients

Airtel
Canon
Contec
HoneyWell
Kriloskar
Pwc Logo
Samsung
Tata Teleservices

Whitepaper

Read All